GSK (GLAXF) discloses issued shares and voting-rights denominator

Rhea-AI Filing Summary

GSK plc notifies the market of its issued share capital and total voting rights. The company reported 4,315,407,340 ordinary shares of 31.25 pence each, of which 247,769,844 are held in treasury, producing a total of 4,067,637,496 voting rights. The notice states this figure may be used by shareholders as the denominator when determining whether they must notify changes in their holdings under applicable disclosure rules and provides an email contact for notifications.

Insights

Corporate Governance Expert

TL;DR: Routine statutory disclosure of issued share capital and voting rights; supports shareholder notification obligations and market transparency.

The filing provides the standard market notification of issued shares, treasury holdings and resulting total voting rights. This is a compliance-driven disclosure intended to ensure shareholders have the correct denominator for regulatory notification thresholds. It does not report changes to capital structure, issuance, buybacks or transfers within the document, so it appears to be a status update rather than a material corporate action. For governance processes, timely and accurate voting-rights figures are necessary for shareholder communication and regulatory certainty.

Securities Analyst

TL;DR: Neutral informational release; provides precise share counts and voting-rights denominator but no financial or transactional impact.

The announcement lists specific totals: 4,315,407,340 ordinary shares issued, 247,769,844 held in treasury, and a total voting-rights figure of 4,067,637,496. These numbers are useful for calculating ownership percentages and notification triggers under disclosure rules, yet there is no indication of recent capital changes, issuance events, or impacts to earnings or balance sheet. Investors and registrars can use the contact email provided for formal notifications or queries.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc

Total Voting Rights and Capital

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 30 September 2025 consisted of 4,315,407,340 shares of 31 ¼ pence each ('Ordinary Shares'), of which 247,769,844 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,067,637,496. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

1 October 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: October 01, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What is the total number of GSK plc (GLAXF) ordinary shares issued?

The company reports 4,315,407,340 ordinary shares issued.

How many GSK plc (GLAXF) ordinary shares are held in treasury?

The filing states 247,769,844 ordinary shares are held in treasury.

What is the total number of voting rights for GSK plc (GLAXF)?

The total number of voting rights is reported as 4,067,637,496.

How should shareholders use the voting-rights figure?

Shareholders may use the voting-rights figure as the denominator to determine whether they must notify changes in their interest under the applicable disclosure rules.

Who can shareholders contact for notifications regarding GSK plc (GLAXF)?

The filing provides the contact email company.secretary@gsk.com for notifications.